国为医药 国为生物

1.  Exhibition Background

The exhibition is held from July 16 to 18, 2025, at the Kuala Lumpur International Trade and Exhibition Centre in Malaysia.

Over 420 global exhibitors and over 12,000 professional visitors attracted numerous international clients, including those from China, Japan, Malaysia, Singapore, Thailand, India, Bangladesh, and other Asian countries, as well as parts of Europe.

Together, they established a platform for exchange across the entire industry chain, encompassing APIs, pharmaceutical equipment, intermediates, finished pharmaceuticals, and packaging solutions.

2.Exhibition Site

The complex and specialty APIs and formulations attracted widespread attention from international clients.

During the busy and vibrant three-day exhibition, the complex and specialty products, including APIs (such as oral/injectable pharmaceutical-grade Fish Oil, Beraprost Sodium, Sucroferric Oxyhydroxide, and Ilaprazole) and formulations (such asdutasteride soft capsules and calcitriol injection/soft capsules), secured preliminary collaboration agreements with several leading companies from various Southeast Asian countries.

3. The Market Opportunities in Southeast Asia

Gowell Pharma participated in the CPHI Southeast Asia Market Analysis and Discussion Forum, where pharmaceutical regulatory authorities from various countries shared their perspectives on the opportunities and challenges of the ASEAN market.

Notably, several leading Southeast Asian pharmaceutical companies expressed strong interest in our complex and specialty products and expressed clear intentions to collaborate. Participating companies expressed their hope that Gowell Pharmaceuticals would expedite its product registration process in PICS member countries to facilitate the successful implementation of bilateral cooperation.

4. After the Exihibition

During a visit to Malaysia's Directorate-General of External Trade, Guowei Pharmaceuticals proactively proposed a supply chain solution for the future development of the Southeast Asian pharmaceutical market.

Leaders in attendance:

Director of the Southeast Asia and Oceania Department—Zhong Runzhang

Executive President of the Sichuan-Chongqing Chamber of Commerce in Malaysia—Wu Xia

Hai-O Group, a Malaysian listed company.

Gowell Pharmaceuticals is fully committed to promoting the Malaysian healthcare industry.

5. Conclusion

At the 2025 CPHI in Kuala Lumpur, Gowell Pharma, through in-depth discussions with local authorities and leading companies, gained a profound insight into the vast development prospects of the Southeast Asian pharmaceutical market. The company will continue to closely follow customer needs, deepen its system certification process, and strive to transform the trust fostered at the exhibition into tangible and sustainable solutions.

Gowell Pharma welcomes you to visit its factory and looks forward to meeting you at the next international exhibition!